Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.
Identifieur interne : 001096 ( PubMed/Corpus ); précédent : 001095; suivant : 001097Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.
Auteurs : Caroline Prunier ; Erwan Bézard ; Jérôme Montharu ; Marina Mantzarides ; Jean-Claude Besnard ; Jean-Louis Baulieu ; Christian Gross ; Denis Guilloteau ; Sylvie ChalonSource :
- NeuroImage [ 1053-8119 ] ; 2003.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Behavior, Animal (drug effects), Dopamine Agents, Female, Image Processing, Computer-Assisted, Iodine Radioisotopes (pharmacokinetics), Macaca fascicularis, Nortropanes (pharmacokinetics), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinson Disease, Secondary (diagnostic imaging), Radiopharmaceuticals (pharmacokinetics), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , pharmacokinetics : Iodine Radioisotopes, Nortropanes, Radiopharmaceuticals.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agents.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- diagnostic imaging : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal.
- Animals, Female, Image Processing, Computer-Assisted, Macaca fascicularis, Tomography, Emission-Computed, Single-Photon.
Abstract
Presymptomatic diagnosis of the loss of nigrostriatal neurons that characterises Parkinson's disease, is a crucial issue for future neuroprotective therapies as degeneration exceeds 70 to 80% when symptoms appear. Here we propose an early diagnosis method that utilises single photon emission computerized tomography (SPECT) coupled to the iodine-123-labelled selective dopamine transporter ligand N-(3-ioprop-2E-enyl)-2-beta-(4-methylphenyl)nortropane ((123)I-PE2I), applying Logan's graphical method for quantification. Sequential (123)I-PE2I SPECT acquisitions were performed in nonhuman primates chronically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine according to a regimen that consistently produces a progressive Parkinsonian state. While classical neurological examination only allows detection of Parkinsonian signs at Day 12 of the protocol of intoxication, the mean distribution volume ratio calculated according to Logan's graphical method is significantly decreased from Day 6 onward, i.e., when animals are clinically normal. (123)I-PE2I SPECT is a very sensitive method to detect presymptomatic lesions of nigrostriatal neurons and the first to be experimentally validated. It could now be used clinically for early diagnosis and follow-up of neuroprotective treatment.
PubMed: 12880809
Links to Exploration step
pubmed:12880809Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.</title><author><name sortKey="Prunier, Caroline" sort="Prunier, Caroline" uniqKey="Prunier C" first="Caroline" last="Prunier">Caroline Prunier</name><affiliation><nlm:affiliation>INSERM U316, Laboratoire de Biophysique médicale et Pharmaceutique, 31 avenue Monge, 37200 Tours, France. c.prunier@chu-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bézard">Erwan Bézard</name></author><author><name sortKey="Montharu, Jerome" sort="Montharu, Jerome" uniqKey="Montharu J" first="Jérôme" last="Montharu">Jérôme Montharu</name></author><author><name sortKey="Mantzarides, Marina" sort="Mantzarides, Marina" uniqKey="Mantzarides M" first="Marina" last="Mantzarides">Marina Mantzarides</name></author><author><name sortKey="Besnard, Jean Claude" sort="Besnard, Jean Claude" uniqKey="Besnard J" first="Jean-Claude" last="Besnard">Jean-Claude Besnard</name></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name></author><author><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12880809</idno><idno type="pmid">12880809</idno><idno type="wicri:Area/PubMed/Corpus">001096</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001096</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.</title><author><name sortKey="Prunier, Caroline" sort="Prunier, Caroline" uniqKey="Prunier C" first="Caroline" last="Prunier">Caroline Prunier</name><affiliation><nlm:affiliation>INSERM U316, Laboratoire de Biophysique médicale et Pharmaceutique, 31 avenue Monge, 37200 Tours, France. c.prunier@chu-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bézard">Erwan Bézard</name></author><author><name sortKey="Montharu, Jerome" sort="Montharu, Jerome" uniqKey="Montharu J" first="Jérôme" last="Montharu">Jérôme Montharu</name></author><author><name sortKey="Mantzarides, Marina" sort="Mantzarides, Marina" uniqKey="Mantzarides M" first="Marina" last="Mantzarides">Marina Mantzarides</name></author><author><name sortKey="Besnard, Jean Claude" sort="Besnard, Jean Claude" uniqKey="Besnard J" first="Jean-Claude" last="Besnard">Jean-Claude Besnard</name></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name></author><author><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author></analytic><series><title level="j">NeuroImage</title><idno type="ISSN">1053-8119</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Behavior, Animal (drug effects)</term><term>Dopamine Agents</term><term>Female</term><term>Image Processing, Computer-Assisted</term><term>Iodine Radioisotopes (pharmacokinetics)</term><term>Macaca fascicularis</term><term>Nortropanes (pharmacokinetics)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Parkinson Disease, Secondary (diagnostic imaging)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Iodine Radioisotopes</term><term>Nortropanes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Image Processing, Computer-Assisted</term><term>Macaca fascicularis</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Presymptomatic diagnosis of the loss of nigrostriatal neurons that characterises Parkinson's disease, is a crucial issue for future neuroprotective therapies as degeneration exceeds 70 to 80% when symptoms appear. Here we propose an early diagnosis method that utilises single photon emission computerized tomography (SPECT) coupled to the iodine-123-labelled selective dopamine transporter ligand N-(3-ioprop-2E-enyl)-2-beta-(4-methylphenyl)nortropane ((123)I-PE2I), applying Logan's graphical method for quantification. Sequential (123)I-PE2I SPECT acquisitions were performed in nonhuman primates chronically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine according to a regimen that consistently produces a progressive Parkinsonian state. While classical neurological examination only allows detection of Parkinsonian signs at Day 12 of the protocol of intoxication, the mean distribution volume ratio calculated according to Logan's graphical method is significantly decreased from Day 6 onward, i.e., when animals are clinically normal. (123)I-PE2I SPECT is a very sensitive method to detect presymptomatic lesions of nigrostriatal neurons and the first to be experimentally validated. It could now be used clinically for early diagnosis and follow-up of neuroprotective treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12880809</PMID><DateCreated><Year>2003</Year><Month>07</Month><Day>25</Day></DateCreated><DateCompleted><Year>2003</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1053-8119</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.</ArticleTitle><Pagination><MedlinePgn>810-6</MedlinePgn></Pagination><Abstract><AbstractText>Presymptomatic diagnosis of the loss of nigrostriatal neurons that characterises Parkinson's disease, is a crucial issue for future neuroprotective therapies as degeneration exceeds 70 to 80% when symptoms appear. Here we propose an early diagnosis method that utilises single photon emission computerized tomography (SPECT) coupled to the iodine-123-labelled selective dopamine transporter ligand N-(3-ioprop-2E-enyl)-2-beta-(4-methylphenyl)nortropane ((123)I-PE2I), applying Logan's graphical method for quantification. Sequential (123)I-PE2I SPECT acquisitions were performed in nonhuman primates chronically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine according to a regimen that consistently produces a progressive Parkinsonian state. While classical neurological examination only allows detection of Parkinsonian signs at Day 12 of the protocol of intoxication, the mean distribution volume ratio calculated according to Logan's graphical method is significantly decreased from Day 6 onward, i.e., when animals are clinically normal. (123)I-PE2I SPECT is a very sensitive method to detect presymptomatic lesions of nigrostriatal neurons and the first to be experimentally validated. It could now be used clinically for early diagnosis and follow-up of neuroprotective treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prunier</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U316, Laboratoire de Biophysique médicale et Pharmaceutique, 31 avenue Monge, 37200 Tours, France. c.prunier@chu-tours.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bézard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Montharu</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mantzarides</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Besnard</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Baulieu</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Guilloteau</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chalon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C402415">I123-PE2I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009662">Nortropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009662" MajorTopicYN="N">Nortropanes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12880809</ArticleId><ArticleId IdType="pii">S1053811903001630</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:12880809
|texte= Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12880809" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |